The invention provides methods for administering necroptosis or interferon signaling inhibitors for treating or preventing immune-related tissue injury in a subject having an inactivating mutation in ATG16L1. The invention also provides organoid cultures and co-cultures and methods of use for identifying therapeutic agents.

The invention provides methods for administering necroptosis or interferon signaling inhibitors for treating or preventing immune-related tissue injury in a subject having an inactivating mutation in ATG16L1. The invention also provides organoid cultures and co-cultures and methods of use for identifying therapeutic agents.

The present disclosure provides methods and systems for generating biological tissues that are configured for folding into a pre-determined three-dimensional form. The present disclosure utilizes contractile cells for folding a biological tissue into a three-dimensional shape. The methods include disposing a pattern of contractile cells on a surface that includes fibers actuated by the contractile cells and folding of the surface by the action of the contractile cells on the fibers. Tissues generated using the methods and systems of the present disclosure are also provided.

The present disclosure provides methods and systems for generating biological tissues that are configured for folding into a pre-determined three-dimensional form. The present disclosure utilizes contractile cells for folding a biological tissue into a three-dimensional shape. The methods include disposing a pattern of contractile cells on a surface that includes fibers actuated by the contractile cells and folding of the surface by the action of the contractile cells on the fibers. Tissues generated using the methods and systems of the present disclosure are also provided.

The present invention generally relates to therapeutic compositions and methods for treating cancer patients. The compositions and methods can increase efficacy of an anti-cancer therapy, or treat, prevent, or inhibit an oncology-treatment induced condition (OTIC) induced by an anti-cancer therapy. The therapeutic compositions comprise microbial compositions and, optionally, an anti-cancer therapeutic agent. The methods comprise administering a therapeutic composition comprising a microbial composition and administering an anti-cancer therapy.

The present invention generally relates to therapeutic compositions and methods for treating cancer patients. The compositions and methods can increase efficacy of an anti-cancer therapy, or treat, prevent, or inhibit an oncology-treatment induced condition (OTIC) induced by an anti-cancer therapy. The therapeutic compositions comprise microbial compositions and, optionally, an anti-cancer therapeutic agent. The methods comprise administering a therapeutic composition comprising a microbial composition and administering an anti-cancer therapy.

The present invention generally relates to therapeutic compositions and methods for treating cancer patients. The compositions and methods can increase efficacy of an anti-cancer therapy, or treat, prevent, or inhibit an oncology-treatment induced condition (OTIC) induced by an anti-cancer therapy. The therapeutic compositions comprise microbial compositions and, optionally, an anti-cancer therapeutic agent. The methods comprise administering a therapeutic composition comprising a microbial composition and administering an anti-cancer therapy.

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.